Atara Biotherapeutics (ATRA) 17th Annual LD Micro Main Event Conference summary

Platform overview and product pipeline

• Utilizes Epstein-Barr virus-specific T-cells to develop therapies for EBV-driven diseases and as a platform for CAR-T therapies.

• Lead product, Tab-cel (Ebvallo), is commercialized in Europe and targets ultra-rare lymphoma with no current approved therapies.

• CAR-T pipeline includes ATA3219 (CD19 CAR) in phase 1 for lupus and non-Hodgkin lymphoma, and ATA3431 (dual CD19/CD20 CAR) with IND expected in H2 2025.

• Platform avoids lymphodepletion, offering outpatient infusions and reduced patient burden.

• Over 600 patients treated across programs, more than any other allogeneic company in the space.

Manufacturing and scalability advantages

• Allogeneic approach enables rapid delivery (within three days) and scalability, overcoming autologous CAR-T limitations.

• One donor can provide hundreds to thousands of doses, reducing cost and increasing access.

• Platform uses partial allelic matching and EBV-specific T-cell receptors to minimize graft-versus-host disease and rejection.

• Avoids gene editing, reducing genomic instability and manufacturing inefficiency.

Clinical and preclinical data highlights

• Tab-cel shows a 50% lifetime objective response rate in its indication.

• Preclinical data for ATA3219 and ATA3431 demonstrate superior efficacy and lower cytokine release compared to autologous CAR-Ts.

• Dual-targeted CAR-T (CD19/CD20) addresses antigen escape, with preclinical models showing extended survival and strong anti-tumor activity.

• Lupus and other autoimmune indications show promise for long-term drug-free remission, driving industry interest.